summary

The Democrats will probably win the next election.’

‘The coin is just as likely to land heads as tails.’

‘There’s a 30% chance of rain tomorrow.’

‘The probability that a radium atom decays in one year is roughly 0.0004.’

One regularly reads and hears probabilistic claims like these. But what do they mean? This may be understood as a metaphysical question about what kinds of things are probabilities, or more generally as a question about what makes probability statements true or false. At a first pass, various interpretations of probability answer this question, one way or another.

However, there is also a stricter usage: an ‘interpretation’ of a formal theory provides meanings for its primitive symbols or terms, with an eye to turning its axioms and theorems into true statements about some subject. In the case of probability, Kolmogorov’s axiomatization (which we will see shortly) is the usual formal theory, and the so-called ‘interpretations of probability’ usually interpret it. That axiomatization introduces a function ‘PP’ that has certain formal properties. We may then ask ‘What is PP?’. Several of the views that we will discuss also answer this question, one way or another.

Let's start with the truth!

Support the Broken Science Initiative.
Subscribe today →

Leave A Comment

recent posts

    If you're seeing this page, you are not currently logged into a profile with access to Affiliate Owners / Medical.

    At the 2026 Unbreakable Health Retreat in Miami, Emily Kaplan hosted a panel with Bob Kaplan, Professor Thomas Seyfried, and Dr. Derek Lee on what it means to treat cancer as a metabolic disease. They discussed the glucose-ketone index (GKI), nutritional ketosis, and strategies aimed at restricting the fuels cancer cells depend on while considering how metabolic therapy can fit alongside standard cancer treatment.

    The conversation also addressed the practical realities patients face when trying to pursue a metabolic approach within the conventional oncology system, including questions about nutrition, repurposed drugs, inherited cancer risk, and how to evaluate different treatment options. Seyfried and Lee connected these clinical questions back to mitochondrial dysfunction, fermentation, and the metabolic vulnerabilities that may offer additional targets for cancer treatment.

    An abbreviated version of this discussion is available here, for free.

    At the 2026 Unbreakable Health Retreat in Miami, Professor Thomas Seyfried presented the case that cancer is fundamentally a mitochondrial metabolic disease rather than primarily a genetic one. He contrasts the dominant somatic mutation theory with a metabolic model in which impaired mitochondrial respiration drives a shift toward fermentation, dysregulated cell growth, and the mutations commonly associated with cancer.

    Citing the work of Otto Warburg and research from his lab at Boston College, Seyfried explains how cancer cells rely heavily on fermentable fuels—particularly glucose and glutamine—and why mitochondrial dysfunction sits upstream of many of the genetic abnormalities seen in tumors. He also discusses reactive oxygen species, altered cellular signaling, and the role of mitochondria in regulating cell growth and behavior.

    The presentation then turns to the therapeutic implications of this model. Seyfried explains strategies aimed at placing tumor cells under metabolic stress by restricting the fuels they depend on, including ketogenic metabolic therapy and approaches targeting glucose and glutamine. For Seyfried, the therapeutic target follows directly from the biology: restrict the fuels cancer cells depend on, exploit their metabolic weaknesses, and treat mitochondrial dysfunction as the central feature of the disease.

    An abbreviated version of this discussion is available here, for free.

    MetFix and BSI Members can view the full 54-minute video.